

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Clayton et al.

Docket No.

PG3749USW

Serial No.
10/049,142Filing Date
February 5, 2002Examiner
M. BaharGroup Art Unit
1617

Use of EP4 Receptor Ligands in the Treatment of Neuropathic Pain and Colon Cancer

AUG 7 0 2004



I hereby certify that this Transmittal of Amendment After Final Pursuant to 37 CFR 1.116 w/documents
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

on August 17, 2004
(Date)

Valerie L. Phillips

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Clayton et al.

Docket No.

PG3749USW

Serial No.
10/049,142Filing Date
February 5, 2002Examiner
M. BaharGroup Art Unit
1617

Use of EP4 Receptor Ligands in the Treatment of Neuropathic Pain and Colon Cancer

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	8 -	23 =	0	0 x \$18.00	\$0.00
INDEP. CLAIMS	1 -	8 =	0	0 x \$86.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- No additional fee is required for amendment.
- Please charge Deposit Account No. 07-1392 in the amount of
- A check in the amount of to cover the filing fee is enclosed.
- The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392
 - Any additional filing fees required under 37 C.F.R. 1.16.
 - Any patent application processing fees under 37 CFR 1.17.

Signature

Lorie Ann Morgan
Reg. No. 38,181

Dated: 17 Aug 2004

I certify that this document and fee is being deposited on 17 Aug 2004 with the U.S. Postal Service as first class mail under 37C.F.R. 1.8 and is addressed to the
for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

CC:

AF/1617
JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

N. Clayton et al.,

Serial No.: 10/049,142

Examiner: S. Sharareh

Filing Date: 5 February 2002

Art Unit: 1617

For: USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT
OF NEUROPATHIC PAIN AND COLON CANCERDirector of the U.S. Patent and Trademark Office,
P.O. Box 1450
Alexandria, VA 22313-1450AMENDMENT AFTER FINAL PURSUANT TO 37 C.F.R. §1.116

Sir:

Responsive to the final Office Action mailed 17 June 2004, please amend and reconsider the instant application in view of the following amendments and remarks. The following amendments place the claims in condition for allowance or at a minimum, narrow the issues for appeal. Accordingly, it is respectfully submitted that the instant Amendment is proper under 37 C.F.R. §1.116.

Amendments to the Claims appear on pages 2-3 of this paper.

Remarks appear on pages 4-5 of this paper.